Med-X: Advancing Brain-Computer Interfaces Toward 2035 Clinical Use

Shanghai Jiao Tong University Journal Center

Brain-computer interfaces (BCIs) have advanced rapidly over the past decades, evolving from experimental concepts into powerful tools for neuroscience research and emerging clinical applications. By enabling direct communication between the brain and external devices, BCIs have demonstrated remarkable potential in restoring movement, communication, and neurological functions. However, despite substantial technological progress and growing investment, relatively few BCI systems have achieved widespread clinical adoption or sustainable commercialization. Bridging this gap requires not only technological innovation but also a clearer understanding of which clinical applications should be prioritized to maximize patient benefits and societal impact.

Recently, a Perspective article titled "Identifying brain-computer interface translational priorities with an outlook on the field in 2035" was published in Med-X. The authors introduce a quantitative framework to evaluate the urgency, importance, and economic impact of 12 neurological and neuropsychiatric conditions relevant to BCI applications. By combining disease-burden analysis with an assessment of technological progress and translational challenges, the article identifies strategic priorities for clinical development and outlines a long-term vision for a sustainable BCI ecosystem.

1. Technological Advances: From Neural Interfaces to Clinical Applications

BCI technologies can be broadly classified into invasive, semi-invasive, and non-invasive systems according to their interface with the nervous system. Invasive approaches, including intracortical electrodes and deep brain stimulation, provide high-resolution neural recording or targeted stimulation, supporting applications such as motor control, communication restoration, and neurological intervention. Semi-invasive systems, such as electrocorticography, offer an alternative balance between signal quality and surgical invasiveness. Meanwhile, non-invasive technologies, including electroencephalography and transcranial brain stimulation, provide more accessible approaches for neurorehabilitation and psychiatric treatment. Advances in electrode design, wireless systems, and artificial intelligence have further improved neural decoding and adaptive stimulation. Nevertheless, long-term reliability, safety, cost, and clinical scalability remain major barriers to translating these advances into widely available medical products.

2. Clinical Prioritization: Evaluating Urgency, Importance, and Impact

To identify where BCI development could deliver the greatest societal benefit, the authors evaluated 12 neurological and neuropsychiatric conditions using an urgency–importance–impact framework. Importance was quantified using disability-adjusted life years (DALYs) in 2021, reflecting the current disease burden, while urgency was defined by the projected relative increase in DALYs between 2021 and 2035. Economic costs were incorporated as an additional indicator of societal impact. This analysis highlights Alzheimer's disease and other dementias, stroke, depression, and anxiety as major strategic priorities. Importantly, these rankings reflect population-level healthcare needs rather than the current effectiveness or technological readiness of BCIs for each condition. The framework therefore provides an evidence-informed basis for directing research attention and investment toward high-burden clinical challenges.

3. High-Priority Applications: Addressing Major Neurological and Psychiatric Needs

Among the conditions analyzed, Alzheimer's disease and related dementias show the greatest projected increase in disease burden, highlighting an urgent need for new therapeutic approaches. Although BCI applications for dementia remain exploratory, adaptive neuromodulation may eventually provide opportunities to investigate and regulate dysfunctional neural circuits. Stroke represents the largest overall disease burden, making restoration of motor function, communication, and independence a particularly important target for BCI-assisted rehabilitation. Depression and anxiety also emerge as high-priority conditions because of their substantial disability and economic impact. For treatment-resistant depression, invasive neuromodulation may offer potential benefits for selected patients, while non-invasive stimulation approaches could provide more scalable interventions. Together, these applications illustrate how BCI research priorities should be guided by both unmet clinical needs and realistic therapeutic opportunities.

4. Future Outlook: Building a Sustainable BCI Ecosystem Beyond 2035

Looking toward 2035 and beyond, the authors envision a transition from laboratory demonstrations toward clinically validated and sustainable BCI technologies. Advances in flexible bioelectronics, minimally invasive implantation, wireless communication, and AI-driven closed-loop systems may improve device reliability and enable more personalized neural interfaces. However, technological progress alone will not guarantee successful clinical translation. Long-term device performance, rigorous clinical trials, reimbursement mechanisms, regulatory pathways, and ethical safeguards will be essential for broader adoption. The authors further emphasize that current BCIs, particularly invasive systems, should be recognized as powerful scientific instruments that can advance fundamental understanding of neural mechanisms and support future therapeutic innovation. By aligning basic neuroscience, clinical needs, artificial intelligence, and responsible commercialization, the field may establish a stronger foundation for sustainable development.

/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.